Batioglu 1997.

Methods	Location: Ankara Turkey No. of Centres: 1 Recruitment period: NS
Participants	Inclusion criteria: ovarian endometriomas >3cm unilateral/bilateral No. randomised: 25 No. analysed: 25
Interventions	Post‐surgery medical treatment with triptorelin 3.75 mg IM x 4 weekly for 6 months (n = 13) versus Pre‐surgery and post‐surgery treatment with triptorelin 3.75 mg IM x 4 weekly for 6 months (n = 12)
Outcomes	AFS scores at 6 months Pregnancy rate at 1 year follow up
Notes	Power calculation: NS Funding: NS
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	"randomly allocated into one of the treatment groups, odd numbers in the first group and even numbers in the second
Allocation concealment (selection bias)	High risk	no allocation concealment
Blinding (performance bias and detection bias) All outcomes	High risk	not mentioned, no placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	pregnancy rate reported for all randomised patients
Selective reporting (reporting bias)	Unclear risk	mean AFS scores reported per endometrioma not per patient, pregnancy rate
Other bias	Unclear risk	there were differences between the groups at baseline with regard to mean adhesion scores